$50.00
Cagrilintide is an investigational peptide medication being studied for weight loss and appetite control. It is often researched alone or in combination with GLP-1 medications (like Semaglutide). It is not yet widely FDA-approved as a standalone product as of 2026.
Cagrilintide is a long-acting analog of amylin, a hormone naturally released by the pancreas along with insulin. Amylin plays a role in satiety (feeling full) and blood sugar regulation.
Helps reduce hunger signals, making it easier to eat less.
Slows how quickly the stomach empties, helping you feel full longer after meals.
Being studied for significant weight reduction, especially when combined with GLP-1 medications.
Supports more stable blood glucose levels by slowing nutrient absorption and working alongside insulin.
May help decrease cravings and improve portion control.
Cagrilintide mimics amylin, which:
When combined with GLP-1 drugs, it may provide dual appetite and metabolic control.
Cagrilintide is a next-generation weight management peptide that works by reducing appetite, increasing fullness, and supporting blood sugar control, especially when paired with GLP-1 therapies.
